Objective: to evaluate the frequency of diabetes mellitus and glucose intolerance in patients with cystic fibrosis treated at the Pediatric Gastroenterology Service of HC-FMRP-USP.
Introduction
Cystic fibrosis (mucoviscidosis) is a generalized disorder in the secretion process of all exocrine glands. 1 It is a frequent disease, especially in Caucasian populations. Cystic fibrosis (CF) is related to autosomal recessive inheritance characterized by abnormality in water and chloride transport through the epithelium in sweat glands, the pancreas, lungs, and intestines. This results in hyperviscosity of ductular secretions. In the pancreas, CF culminates with obstruction and fibrosis. Pancreatic involvement in CF is common, with most patients developing gland fibrosis and exocrine insufficiency. 2 Endocrine involvement is also frequent in CF, with a significant number of patients developing some level of glucose intolerance. 3, 4 The pathophysiological mechanism of glucose intolerance in mucoviscidosis is controversial. Several studies have clearly shown involvement of insulin secretion in cystic fibrosis patients, [5] [6] [7] [8] which is a result of destruction of islets by fibrosis, fat replacement, and amyloid deposits. 2, 9, 10 Alterations in sensitivity to insulin have also been associated with CF. 8, [11] [12] [13] [14] [15] Involvement of insulin resistance is related to several mechanisms, including recurrent or chronic lung infections, subclinical hepatic fibrosis, increase in counter-regulating hormones (cortisol and catecholamines), increased levels of cytokines (interleukin and TNF-alpha), and, in patients with manifest diabetes, glucotoxicity. Elevated hepatic glucose production, which is secondary to insulin resistance in the liver, was shown in nondiabetic, CF patients. 13, 16 Previous studies have established a direct correlation between onset of diabetes mellitus and exocrine insufficiency. 17, 18 These findings suggest that despite insulin resistance being involved in this process, the main determinant factor in development of diabetes would be liver involvement.
Diabetes mellitus (DM) is a potential complication in CF children, and it may lead to several chronic degenerative disorders that could be delayed with proper treatment. In this sense, it is important to understand when DM affects these patients in order to allow for adequate diagnosis and early treatment. In our study, we assessed the frequency of DM and glucose intolerance in CF patients, followed-up at the Gastropediatric Services of the Hospital de Clínicas, Medical School of Ribeirão Preto, Universidade de São Paulo (HC-FMRP-USP), in correlation with duration of clinically manifest CF and exocrine pancreatic function.
Patients and methods
We carried out an analytic cross-sectional study of 25 CF patients. Patients included in our study were being followed-up at the HC-FMRP between March 1998 and June 1999 and presented diagnosis of cystic fibrosis verified by clinical status and analysis of sweat for chloride concentration, according to technique described by Gibson and Cooke. 19 Out of 30 eligible patients, we excluded five (16.7%) who presented active lung infection diagnosed clinically and radiologically and/or who refused to participate in the study. Our population of 25 patients represented 83.3% of CF patients of the Gastropediatric Services during the study period. Patients and parents/guardians were informed of study objectives and methods, with reassurance that adequate treatment would be provided according to exam results. Informed consent was obtained from all parents, guardians or patients in the study population. Our study was approved by the Ethics Committee of the Hospital de Clínicas, FMRP-USP.
Patients were submitted to tests according to technical feasibility related to age and ability to cooperate. Glycemia was verified in all 25 patients after an 8 to 14-hour fasting period, without diet restrictions for the 3 days prior to the test. Seventeen patients were submitted to oral glucose tolerance test (OGTT) with 75 g of glucose for adolescents and adults and 1.75 g/kg for children. We were able to collect samples for serum insulin in only 15 patients. Two patients were not tested for insulinemia due to insufficient collection of material.
Exocrine pancreatic function was assessed according to intake of enzyme capsules (1 capsule = 4,000 units/kg/day). Duration of the disease was calculated according to date of diagnosis, reported in medical records, to the date in which exams were carried out.
Glucose tolerance testes were assessed according to World Health Organization (WHO) and National Diabetes Data Group (NDDG) criteria. 20, 21 Patients with two-hour glycemia greater than 200 mg/dl were classified as diabetic; whereas patients with two-hour glycemia between 140 and 200 mg/dl or other intervals of glycemia greater than 200 mg/dl were classified as glucose intolerant. We also assessed serum insulin levels during OGTT. Serum glucose was determined in duplicates using the glucose oxidase method. 22 Serum insulin was determined by solid-phase doubleantibody radioimmunoassay for human insulin (Diagnostic Products Corporation, Los Angeles, CA). All samples from the same test were dosed in duplicates during the same assay; results were expressed in micro-U/ml.
We also calculated the area under the glycemia (G) and insulin (I) curves during OGTT. Next, we calculated the ratio of I:G according to values obtained. Thus, we were able to carry out an overall assessment of glycemic behavior and insulin secretion during the tests, as well as of the interaction between these two variables. 23 Our results were statistically analyzed using Spearman correlation coefficient and linear regression of parameters. Statistical significance was considered for 5% (P < 0.05).
Results
The age average of our population was 8 years and 10 months, for an age range of 9 months to 30.8 years. Fourteen (56%) patients were males and 11 (44%) were females. There were 24 (96%) Caucasians and one (4%) Mulatto. Average duration of disease (time from diagnosis to exams) was 6 years and 11 months, for a range of 3 months to 30.4 years.
Out of the 25 patients, 15 were submitted to OGTT and concomitant insulinemia dosage determination; two patients were submitted to OGTT alone; and eight patients were submitted to assessment of baseline glycemia alone. Results are presented in Table 1 .
One patient (FB) presented two-hour glycemia in OGTT greater than 200 mg/dl, thus fulfilling the criteria for diagnosis of diabetes mellitus. Moreover, during OGTT we also detected three patients with glucose intolerance: patients DE and RFF presented glycemia greater than 200 mg/dl and patient RRP presented two-hour glycemia greater than 140 mg/dl. Patient GSR presented high serum levels of insulin despite having the glycemia curve within normal limits. Table 2 presents age, duration of disease, and intake of pancreatic enzyme capsules (capsules per kg of weight) according to each patient. Table 2 also presents areas under the curves of insulinemia and glycemia during OGTT and the ratio between these two areas (I:G).
Analysis of results indicated inverse (r=-0.57) and significant (P=0.026) correlation between patient age and pancreatic enzyme capsule intake/kg/day. The relation between duration of manifest disease and capsule intake was also inverse (r=-0.33), but not statistically significant. 
* Patients with abnormal levels Figures 1 and 2 present the relation between duration of clinically manifest disease and areas under glycemia and insulinemia curves during OGTT. Assessment of these results indicated a direct (r=0.64) and statistically significant (P=0.01) correlation between the two variables. Relation between duration of disease and areas under glycemia curves in OGTT (r=0.43) and I:G ratio (r=0.36) was also direct, but not statistically significant. Figure 3 presents the relation between capsule intake and areas under curves of insulinemia during OGTT. The correlation between capsule intake and area under curves of insulinemia was inverse and statistically significant (r=-0.53; P=0.042, respectively). This was also observed for the correlation between capsule intake and I:G ratio (r=-0.53; P=0.04, respectively). There was no correlation between capsule intake and area under glycemia curves. 
Discussion
Abnormalities in glucose tolerance are well-known complications in patients with CF. According to epidemiological data, approximately 50% of patients over 18 years of age present some degree of glucose intolerance; 3 moreover, approximately the same percentage of patients at 30 years present clinically manifest diabetes. 4 Considering the method for selection, and the size, of our population, it is clear that our objectives did not include determining prevalence of alterations in glucose tolerance in CF patients. However, we did observe that prevalence of glucose intolerance in this group of patients was in agreement with previously described results. We verified a direct correlation between duration of disease and serum glucose levels, represented by the area under curve of glucose ( Figure 1) ; this finding shows a progression of glucose intolerance in these patients. Only one patient was diagnosed with diabetes mellitus, who was also the older patient and with longer It is important to underscore that we were not able to carry out a complete study of glucose tolerance with insulinemia in all eligible patients; this may have contributed to increase the detection of abnormalities in our population.
We assessed results of glucose tolerance in our patients according to WHO and NDDG criteria. 20, 21 However, just recently the American Diabetes Association has suggested changes to the criteria, such as lowering fasting glycemia for diagnosis of diabetes mellitus (126 mg/dl instead of 140 mg/dl) and simplifying OGTT. 24 These changes would not change the results on prevalence of diabetes in our population, since patients not diagnosed with diabetes presented fasting glycemia lower than 126 mg/dl.
The occurrence of diabetes mellitus in CF patients has been associated to the exocrine status of the pancreas. The relation between exocrine insufficiency and DM has been described by several authors. 17, 18 In our study, the exocrine secretion capacity was inferred by the number of enzyme capsules taken daily and per kg of weight. There was no correlation between glucose intolerance levels (area under curves of glucose) and exocrine secretion; even the DM patient required low doses of pancreatic enzymes (Table 2) . This result was expected, considering that only two patients were over 18 years of age and that most of our population was younger than 10 years. In younger patients, the pancreatic lesion is probably not severe enough to affect insulin secretion; thus, the glycidic balance is maintained. The assessment of exocrine function according to capsule intake is controversial, since patients who were clinically balanced in their digestive function may have used pancreatin doses higher than what they actually needed; also, dosages per kg of weight for children are usually higher than adult and adolescent doses.
In addition to pancreatic involvement, other mechanisms have been associated to the development of glucose intolerance in CF patients. Others have reported abnormalities in peripheral and hepatic sensitivity to insulin. 8, [11] [12] [13] [14] [15] In our study, we observed a significant correlation between insulinemia (indicated by the area under curve of insulin) and duration of clinically manifest disease ( Figure 2) ; this finding indicates progressive insulin resistance related to this clinical status.
It was not our objective to assess possible mechanisms or factors involved in insulin resistance of CF, such as catabolism of the disease, intercurrent infections, hepatic fibrosis, glucotoxicity, elevated levels of counter-regulation hormones, and cytokines. Hepatic resistance, recently demonstrated by Hardin et al. 13 would result in increased hepatic production and compensatory hyperinsulinemia. Peripheral sensitivity to insulin has been a matter of great controversy. Increased, 15 decreased, 8, [11] [12] [13] and unaltered 4, 14 sensitivities have been reported in CF patients. In our study, only one patient was diabetic. This finding is converse to the possibility that insulin resistance is secondary to hyperglycemia (glucotoxicity), as speculated by some authors. 8, 25 As indicated in Figure 2 , the only DM patient in our population, who aged 30.8 years and had 30.4 years of duration of disease, presented the lowest levels of insulin (area under curve); this suggests that onset of DM depends on, in addition to insulin resistance, involvement of the pancreatic secretion. Our results also suggest that in at least one group of patients insulin resistance is involved in genesis of glucose intolerance in CF, and that it probably precedes endocrine pancreatic involvement, which is determinant of DM.
